GLP-1 & Metabolic
Metabolic health, appetite regulation, and modern weight management.
116 articles in GLP-1 & Metabolic · page 4 of 10
How Big Should Your Calorie Deficit Be?
A calorie deficit is just TDEE minus what you eat. Here is how big to make it, a moderate 10-25% below maintenance, and why bigger isn't faster.
Read →How Much Protein on Wegovy or Zepbound: Grams Per Day
How much protein on Wegovy or Zepbound? Evidence-based daily gram targets (~1.6–2.2 g/kg) and a per-meal number to protect muscle while appetite is gone.
Read →How to Calculate Your TDEE: The Mifflin-St Jeor Method
How to calculate TDEE with the Mifflin-St Jeor equation and activity multipliers — a worked example, the full table, and why it is an estimate.
Read →Macro Split for Fat Loss: Calories First, Then Macros
There is no magic ratio. Set the calorie deficit first, anchor protein and a fat floor, then let carbs fill the rest — with the actual math.
Read →Semaglutide Weight Loss by Month: What the Trial Data Actually Shows
Semaglutide weight loss by month: the STEP 1 trial's ~15% average at 68 weeks, why the early months are slow, and what a normal trajectory looks like.
Read →Semaglutide and Tirzepatide Titration Schedules: When to Step Up
The full semaglutide dosage chart and tirzepatide dose schedule from the FDA labels, week by week — plus when to step up a dose and when to hold.
Read →GLP-1S Explained: What the Product Code Denotes and the Evidence Behind It
GLP-1S is a vendor product code, not a molecule. What it denotes, the semaglutide science it points at, and why a grey vial is not the FDA drug.
Read →GLP-2T Explained: The Dual-Agonist Product Code and the Evidence
GLP-2T is a vendor code for a tirzepatide-class dual agonist. The drug-class science is strong; the vial in your hand is unverified. The honest split.
Read →GLP-3R Explained: The Triple-Agonist Product Code and the Evidence
GLP-3R is a vendor product code for a retatrutide-class triple agonist. The science is real and phase 2; the grey-market vial is not the drug.
Read →Are GLP-1s Safe Long-Term?
GLP-1 drugs have over a decade of diabetes use and a shorter obesity record. What the multi-year data shows, and what it still cannot answer.
Read →Cagrilintide: The Amylin Analog, Explained
Cagrilintide mimics the pancreatic hormone amylin. Paired with semaglutide as CagriSema it is Novo's next obesity bet — but not yet approved.
Read →GLP-1s and Constipation: Managing the Other GI Effect
Nausea gets the headlines, but constipation is one of the most common GLP-1 side effects. Why it happens, and what helps.
Read →